Search Results
Jan 13, 2026, 09:00 ET Aignostics Announces New State-of-the-Art Pathology Foundation Model
Atlas H&E-TME, its application for tumor microenvironment profiling in H&E slides. Atlas 2 will also be available for licensing."Atlas 2 demonstrates
More news about: Aignostics
Jan 13, 2026, 09:00 ET Aignostics anuncia un nuevo modelo de vanguardia para la base de la patología
su cartera de productos, incluyendo Atlas H&E-TME, su aplicación para el perfilado del microambiente tumoral en portaobjetos H&E. Atlas 2 también estará disponible para licencia."Atlas
More news about: Aignostics
Jan 13, 2026, 09:00 ET Aignostics annonce un nouveau modèle de fondation de pathologie à la pointe de la technologie
Atlas H&E-TME, son application de profilage du microenvironnement tumoral dans les lames d'hématoxyline et d'éosine. Atlas 2 sera également disponible sous
More news about: Aignostics
Jan 07, 2026, 05:14 ET BABYMONSTER沸騰小巨蛋 巡演終站熱力難忘
https://www.prnewswire.com/apac/zh/news-releases/babymonster--302655075.htmlSOURCE TME live
More news about: TME live
Dec 17, 2025, 06:18 ET Karmanos Cancer Institute Welcomes New Medical Oncologist to Thoracic Oncology and Phase I Clinical Trials Teams
biomarkers, small cell lung cancer (SCLC) therapies, precision oncology and tumor agnostic therapies, immune therapies and modulation in cancer, metabolomic-TME interactions in SCLC, biomarker development, and understanding NET plasticity and evolution to SCLC. He is also part of the phase I team, which is a
More news about: Karmanos Cancer Institute
Dec 08, 2025, 07:50 ET TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
activity of MDSCs. MDSCs are a heterogeneous population of immature myeloid cells that contribute to creating an immunosuppressive tumor microenvironment (TME) by suppressing anti-tumor immune responses. The study showed that antagonism of the DOR with a specific inhibitor modulated a variety of direct and
More news about: TuHURA Biosciences, Inc.
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study. American Society of Hematology 2025 Annual Meeting. Accessed December 2025.2 Dr. Costa L, et al. Long-term
More news about: Johnson & Johnson
Nov 19, 2025, 08:54 ET IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
Japanese Breast Cancer Society Conference, the 2025 European Society of Breast Imaging ("EUSOBI") Congress, Aptitude Health's Targeted Medical Education (TME) Take the Lead in Breast Cancer Care Fall Summit 2025 in New Orleans which focused on breast surgeons, as well as a 2-day hands on training at the Percutaneous
More news about: IceCure Medical
Nov 12, 2025, 04:00 ET Tencent Music Entertainment Group Announces Third Quarter 2025 Unaudited Financial Results
SHENZHEN, China, Nov. 12, 2025 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced its unaudited financial results
More news about: Tencent Music Entertainment Group
Nov 10, 2025, 08:30 ET Rebuilding the Tumor Microenvironment for In Vitro Discovery, Upcoming Webinar Hosted by Xtalks
TORONTO, Nov. 10, 2025 /PRNewswire/ -- A deeper understanding of the tumor microenvironment (TME) is vital for advancing cancer research and developing therapies. Traditional tumor models remain limited by interspecies differences, variable reproducibility
More news about: Xtalks
Nov 05, 2025, 07:00 ET HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
signaling to restore exhausted T-cell function Trap TGFβ to overcome stromal and immune exclusion in tumor microenvironment (TME) This tripartite approach aims to overcome the limitations of existing checkpoint inhibitors by activating
More news about: HanchorBio Inc.
Nov 04, 2025, 09:01 ET AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
ICB → MAPKi): APC-T-cell interactions in tumor margins associated with better outcomes; macrophage interactions in outer tumor microenvironment (TME) indicated poorer prognosis. The study shows that where immune cells are located and how they interact
More news about: Bio-Techne Corporation
Oct 30, 2025, 17:31 ET Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
& Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, among others. About DelveInsight DelveInsight is
More news about: DelveInsight Business Research, LLP
Oct 29, 2025, 02:05 ET Pemenang Golden Melody Awards JJ Lin Luncurkan Lagu Khusus yang Merayakan 10 Tahun "Honor of Kings", Hit Berikutnya dari Dunia "Gaming"
Kings. Lewat kolaborasi ini, Tencent Music Entertainment (TME) turut memperluas jangkauan game tersebut ke berbagai dimensi — mulai dari visual, gameplay, hingga musik — melalui kampanye kolaboratif dan kemitraan konten. Ke depan, TME akan terus mempererat kemitraan strategis dengan karya
More news about: Tencent Music Entertainment Group
Oct 28, 2025, 05:07 ET Golden Melody Awards Winner JJ Lin Drops the 10th Anniversary Theme Song of Honor of Kings, Marking Gaming's Next Crossover Hit
this partnership, TME empowers the gaming IP to achieve multidimensional expression across visuals, gameplay, and audio via content co-creation and integrated campaigns. The collaboration underscores music's expanding cultural role and reach within gaming ecosystems. Moving forward, TME remains committed
More news about: Tencent Music Entertainment Group
Oct 28, 2025, 04:35 ET Golden Melody Awards Winner JJ Lin Drops the 10th Anniversary Theme Song of Honor of Kings, Marking Gaming's Next Crossover Hit
this partnership, TME empowers the gaming IP to achieve multidimensional expression across visuals, gameplay, and audio via content co-creation and integrated campaigns. The collaboration underscores music's expanding cultural role and reach within gaming ecosystems. Moving forward, TME remains committed
More news about: Tencent Music Entertainment Group
Oct 28, 2025, 04:30 ET Domain Therapeutics Doses First Patients in Phase I/II Trial of DT-7012 Targeting CCR8 in Solid Tumors
CCR8, a receptor predominantly expressed on Tregs within the tumor microenvironment (TME). Leveraging potent ADCC and ADCP mechanisms, DT-7012 effectively eliminates these immunosuppressive cells, transforming the TME into a more immunocompetent state. By disrupting CCR8-mediated immunosuppressive environment,
More news about: Domain Therapeutics
Oct 15, 2025, 08:02 ET Aignostics lanza una aplicación basada en IA para el análisis del microambiente tumoral
con socios biofarmacéuticos líderes, Aignostics anunció hoy la disponibilidad general de Atlas H&E-TME, una aplicación para analizar el microambiente tumoral (TME) en imágenes de H&E. Atlas H&E-TME aborda un obstáculo crítico en la investigación del cáncer al extraer información detallada de
More news about: Aignostics
Oct 15, 2025, 07:59 ET Aignostics führt eine KI-gestützte Anwendung zur Erstellung von Profilen der Tumormikroumgebung ein
mit führenden Biopharma-Partnern gab Aignostics heute die allgemeine Verfügbarkeit von Atlas H&E-TME bekannt, einer Anwendung zur Analyse der Tumormikroumgebung (TME) in H&E-Bildern. Atlas H&E-TME adressiert einen kritischen Engpass in der Krebsforschung, indem es ohne spezielle Färbung oder
More news about: Aignostics
Oct 15, 2025, 07:58 ET Aignostics lance une application alimentée par l'IA pour le profilage du micro-environnement tumoral
biopharmaceutiques de premier plan, Aignostics annonce aujourd'hui la disponibilité générale d'Atlas H&E-TME, une application permettant d'analyser le micro-environnement tumoral (TME) dans les images H&E. Atlas H&E-TME s'attaque à un goulot d'étranglement critique dans la recherche sur le cancer en extrayant
More news about: Aignostics
Oct 15, 2025, 03:00 ET Aignostics Launches AI-Powered Application for Tumor Microenvironment Profiling
with leading biopharma partners, Aignostics today announced the general availability of Atlas H&E-TME, an application for analyzing the tumor microenvironment (TME) in H&E images. Atlas H&E-TME addresses a critical bottleneck in cancer research by extracting deep insights from routine H&E
More news about: Aignostics
Oct 15, 2025, 03:00 ET Aignostics Launches AI-Powered Application for Tumor Microenvironment Profiling
with leading biopharma partners, Aignostics today announced the general availability of Atlas H&E-TME, an application for analyzing the tumor microenvironment (TME) in H&E images. Atlas H&E-TME addresses a critical bottleneck in cancer research by extracting deep insights from routine H&E
More news about: Aignostics
Oct 14, 2025, 17:31 ET Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, VBI Vaccines, TME Pharma, Day One Biopharmaceuticals, Servier, Orbus Therapeutics, TVAX Biomedical, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Forma Therapeutics,
More news about: DelveInsight Business Research, LLP
Oct 14, 2025, 06:00 ET Tencent Music Entertainment Group to Report Third Quarter 2025 Financial Results on November 12, 2025
SHENZHEN, China, Oct. 14, 2025 /PRNewswire/ -- Tencent Music Entertainment Group ("TME", or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that it will report its unaudited
More news about: Tencent Music Entertainment Group
Oct 14, 2025, 02:20 ET 華上生醫抗癌新藥GNTbm-TKI將在ESMO發表
聯合使用時，基於其各自獨特的作用機制，它們具有強大的互補性在調控腫瘤微環境的重塑，能夠將「冷腫瘤」轉化為「熱腫瘤」。當進一步與 ICI 或抗 PD-1/VEGF 雙特異性抗體聯合時，展現出極其卓越的抗腫瘤免疫腫瘤活性，能夠吸引 CTL 滲入腫瘤微環境（TME）中，並激活 CTL 及減少 CTL 衰竭。同時，也能降低免疫抑制型細胞（如 TAM、Treg 和 MDSC）被吸引浸潤在TME中，以達到重塑 TME 的效果，這些機制作用將更有利於獲得腫瘤免疫治療的效益。GNTbm-TKI 單藥治療可望用於治療晚期神經內分泌腫瘤，而GNTbm-TKI + GNTbm-38 或聯合 ICI/抗 PD-1/VEGF 雙特異性抗體將可用於多種晚期實體腫瘤的治療，主要通過其獨特的免疫調節活性和多重激酶抑制機制來實現抗癌治療目標。
More news about: 華上生醫